HNRNPA2B1
HNRNPA2B1 (Heterogeneous nuclear ribonucleoproteins A2/B1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Leukaemia and Non-Hodgkin lymphoma.
Overview
Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles. The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilise the transcripts and minimise tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.25, genetic association 0.04, somatic mutation 0.81). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Hepatocellular Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HNRNPA2B1 (Heterogeneous nuclear ribonucleoproteins A2/B1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Leukaemia and Non-Hodgkin lymphoma.
- 1 · What it is
HNRNPA2B1 (Heterogeneous nuclear ribonucleoproteins A2/B1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Leukaemia and Non-Hodgkin lymphoma.
- 2 · What goes wrong in cancer
Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles.
- 3 · How drugs use it
No product in this corpus aims at HNRNPA2B1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:5033 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P22626 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000122566 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.51, leukaemia 0.54 (GraphQL API, CC0)); IntOGen HNRNPA2B1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles. The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilise the transcripts and minimise tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs. Forms hnRNP particles with at least 20 other different hnRNP and heterogeneous nuclear RNA in the nucleus. Involved in transport of specific mRNAs to the cytoplasm in oligodendrocytes and neurons: acts by specifically recognising and binding the A2RE (21 nucleotide hnRNP A2 response element) or the A2RE11 (derivative 11 nucleotide oligonucleotide) sequence motifs present on some mRNAs, and promotes their transport to the cytoplasm. Specifically binds single-stranded telomeric DNA sequences, protecting telomeric DNA repeat against endonuclease digestion. Location: Nucleus; Nucleus, nucleoplasm; Cytoplasm; Cytoplasmic granule (UniProt). Locus 7p15.2 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Leukaemia: Open Targets association 0.54 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HNRNPA2B1" OR ABSTRACT:"HNRNPA2B1" OR TITLE:"heterogeneous nuclear ribonucleoprotein A2/B1" OR ABSTRACT:"heterogeneous nuclear ribonucleoprotein A2/B1" OR TITLE:"Heterogeneous nuclear ribonucleoproteins A2/B1" OR ABSTRACT:"Heterogeneous nuclear ribonucleoproteins A2/B1" OR TITLE:"HNRNPA2" OR ABSTRACT:"HNRNPA2" OR TITLE:"HNRNPB1" OR ABSTRACT:"HNRNPB1" OR TITLE:"HNRPA2B1" OR ABSTRACT:"HNRPA2B1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HNRNPA2B1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTAL1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Hepatocellular carcinoma, IntOGen.
- TargetMLLT3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), IntOGen, Open Targets Platform.
- TargetLEF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Hepatocellular carcinoma, IntOGen.
- TargetZMYM2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), IntOGen, Open Targets Platform.
- TargetAFF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), IntOGen, Open Targets Platform.
- TargetRPL10
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), IntOGen, Open Targets Platform.
- TargetMLLT1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), IntOGen, Open Targets Platform.
- TargetARID5B
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.